Genomic Health, Inc. (GHDX)
(Delayed Data from NSDQ)
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)
by Zacks Equity Research
Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology.
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Why Is Genomic Health (GHDX) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health Test to Guide Chemo Per New Breast Cancer Rule
by Zacks Equity Research
This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).
Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results
by Zacks Equity Research
The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.
Genomic Health (GHDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Genomic Health (GHDX) delivered earnings and revenue surprises of 20.00% and 2.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Genomic Health (GHDX) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.
Genomic Health (GHDX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Genomic Health (GHDX) delivered earnings and revenue surprises of 17.24% and 1.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
Genomic Health's New Positive Data to Boost Test Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
Why Is Genomic Health (GHDX) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.